New Delhi: Pfizer, the first to apply for emergency use of the Covid-19 vaccine in India, has changed its mind. US pharma company has withdrawn the application given in India. The company has given this information in a conversation with the news agency Reuters. The company has said that the company has taken this decision after meeting with the Drug Regulator in India on Wednesday.
The company said, “Based on the discussions in the meeting and additional information sought by the regulator, the company has decided to withdraw the application at this time.” However, in a conversation with Reuters, the company has expressed the possibility that they will apply again with additional information. Several countries including Britain, Bahrain, Canada have already approved the emergency use of Pfizer.
Pfizer first applied for the emergency use of the vaccine in the country. Presently, the Drug Controller General of India (DCGI) has allowed two vaccinations – Covishield and Covaxin, to be used with restrictions with an emergency. Kovishield is co-produced by Oxford-Estrajaneca. At the same time, it is being manufactured in the world’s largest vaccine manufacturer Serum Institute of India, Pune.
Also, Covaxin has been made by Bharat Biotech and the Indian Council of Medical Research. It is being constructed in Hyderabad. The vaccine program in the country has started on 16 January. On Thursday, the Health Ministry said that 45 lakh people have been vaccinated so far. The government is giving vaccines only to health workers in the first phase.
To keep the Pfizer vaccine, a temperature as low as -70 ° C is required. In this vaccine, synthetic messenger RNA (mRNA) has been used to prepare the immune system against the virus. Britain is the first country to allow this vaccine. 40 million doses have already been ordered for a population of 20 million here.
